BioSpace News Archive

Radiko Holdings (CSE:RDKO) (the “Company”) reports that it intends to rely upon the extension provided by the Canadian Securities Administrators (“CSA”) relating to is interim financial statements, accompanying management discussion and analysis and related CEO and CFO certifications for the period ended June 30, 2020 (the “Q2 Interim Filings”)

MedX Health Corp. ( MDX : TSXV) (“the Company”), announces that there will be a delay in the filing of its Interim Financial Statements and accompanying Management’s Discussion and Analysis, and related CEO and CFO certifications for the Second Quarter ended June 30, 2020 (collectively “Interim Filings”) due to COVID-19 related delays. On May 20, 2020, the Canadian Securities Administrators (CSA) announced that they will

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 2,142,858 shares of common stock of the Company,

Cassiopea SpA announced that the United States Food and Drug Administration approved Winlevi® for the treatment of acne in patients 12 years and older.

BioInvent is fully focused on moving our clinical projects forward. Our successful financing of SEK 625 million has strengthened our institutional investor base and is truly transformative for the company as it allows us to broaden and develop our exciting pipeline and creates a solid financial base going forward.” Martin Welschof, CEO BioInvent.

Alligator Bioscience announced interim safety data from its ongoing clinical Phase I study of the drug candidate ATOR-1017, its wholly owned 4-1BB antibody in development for the treatment of metastasized cancer.

So-Young International Inc., the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, announced its unaudited financial results for the three months ended June 30, 2020.

Sarah Cannon, the Cancer Institute of HCA Healthcare, and Lyell Immunopharma announced a strategic collaboration for the advancement of oncology-focused immune-effector, or T-Cell, therapies.

A Silicon Valley Bank credit facility and additional financing from other lenders increase operational flexibility and support the company’s long-term strategy

TeraRecon Inc., the leading provider of advanced visualization and artificial intelligence solutions, recently launched the Intuition Titanium subscription, a new offering that includes a robust set of enterprise AI capabilities with the inclusion of future AI enhancements.